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HALLMARKS:  CANCER CELL OF ORIGIN 
VS. e-CSCs 
 
Cancer cells are believed to originate from senescent 
cells that have undergone stress-induced cell cycle 
arrest [1-3]. During chronological aging, genetic 
mutations are thought to accumulate in the stem cell 
compartment, resulting in i) oncogene activation, ii) 
tumor suppressor inactivation, as well as iii) a variety of 
genetic chromosomal rearrangements (deletions, 
translocations and duplications) and other epigenetic 
modifications [4-6].  
__________________________________________ 
“Energetic” is defined as “showing great activity or 
vitality; full of energy”. 
Synonyms are: “active, dynamic, vital, vibrant, tireless, 
indefatigable, full of vim and vigour, vigorous, high-
powered, driving, powerful, potent”. 
 
Presumably, cancer cells may arise from senescent cells 
through a process of re-activation, leading from cell 
cycle arrest to hyper-proliferation. It has been proposed 
that telomerase activity (hTERT) catalyzes this 
transition [3].  However, this process of re-activation 
can also be achieved through cellular metabolism [7, 8].   
For example, David Sinclair and his colleagues at 
Harvard Medical School have shown that senescent 
cells suffer from a deficiency of NADH (nicotinamide 
adenine dinucleotide), a key anti-oxidant, and that 
senescent cells can be revived simply by the addition of 
an NADH precursor metabolite (namely, nicotinamide 
riboside) to the cell culture media [7, 8]. These results 
directly imply that the anti-oxidant response may also 
trigger the revival of senescent cells (Figure 1).  
Similarly, cancer stem cells (CSCs) are strictly depen-
dent on NADH, for their propagation as 3D-spheroids 
[9]. Also, CSCs have been shown to over-express 
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CSCs possess a hybrid phenotype,  sharing  key hallmarks of  senescence,  “stemness” and  cancer.    e‐CSCs are
hyper‐proliferative  and  have  elevated  mitochondrial  metabolism,  with  an  NRF2‐mediated  anti‐oxidant
response  signature,  including  glutaredoxin  (GLRX)  and  ALDH3A1  over‐expression,  possibly  related  to  their
escape from senescence. Finally, in e‐CSCs, BCAS1 (Breast carcinoma‐amplified sequence‐1) protein expression
was  up‐regulated  by  >100‐fold.  BCAS1  is  a  candidate  oncogene  associated with  “stemness”  and  aggressive
oncogenic behavior, such as Tamoxifen resistance.  
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classical “embryonic” markers of stemness, such as 























































Therefore, the cancer stem cell of origin [10, 11] would 
be predicted to retain certain properties of senescent 
stem cells, while undergoing a gain-of-function process, 
thereby obtaining new properties of a cancer cell, 
resulting in a chimeric or hybrid phenotype (Figure 2). 
These properties would be expected to include: 
biological markers of senescence; a hyper-proliferative 
phenotype; a very active metabolic program to support 
anabolic growth and proliferation; an anti-oxidant 
response, for driving the revival program, to overcome 
senescence-induced cell cycle arrest [7, 8, 12]; and key 














































cell  cycle  arrest mount  an  anti‐oxidant  defense,  to  increase  their
levels  of NADH.  In  turn,  increased NADH  levels  are  known  to  be
sufficient  to  rescue  senescent  cells  from  cell  cycle arrest, allowing
new cell proliferation, by “re‐activating” or “resuscitating” senescent
cells. Increased mitochondrial power would then drive elevated ATP
production  and  3D  anchorage‐independent  growth,  fostering  the
generation and propagation of the cancer cell of origin.  
Table 1. Expected hallmarks of the cancer cell of origin: Comparison with e‐CSCs.  
Cell Type:  Cancer Cell of Origin e-CSCs 
Properties: Expected Features Observed Features 
1) Cell Cycle Arrest: Senescence Markers Elevated p21-WAF (~17-fold) 
2) Propagation: Hyper-Proliferative  G0/G1: ~35-37%   S-phase:    ~10-18% 
  G2/M: ~32-33%   Polyploid: ~12-17% 
3) Metabolism: Metabolically Active Increased Mitochondrial Mass (~4-fold); High OXPHOS & 
Glycolysis 
4) REDOX: Anti-Oxidant Response ALDH Functional Activity (~9-fold Increased) 
 [Produces NADH] Glutaredoxin-1 (GLRX) (~11-fold Increased) 
 ALDH3A1 (~10-fold Increased) 
QPRT (~4-fold Increased) 
RRM2, GCLC, NQO2 (Each ~2-fold Increased) 
5) “Stemness”: Stem Cell Markers High Flavin-based Auto-fluorescence (FAD/FMN); Large Cell 
Size; Aldefluor (+); Anchorage-Independence;  
 BCAS1 (+)(>100-fold Increased) 
6) Inhibitors: Unknown Mitochondrial OXPHOS Inhibitors and CDK4/6 Inhibitors 
Figure 2.  Cancer stem cell of origin. The cancer stem cell of 
origin  would  be  predicted  to  have  a  chimeric‐  or  hybrid‐
phenotype,  retaining  elements  of  i)  senescent  cells,  ii)  cancer 
cells, and iii) stem cells, as we observe in e‐CSCs.  
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Recently, our laboratory may have fortuitously isolated 
a new tumor cell with a cancer cell of origin phenotype, 
by using flavin-derived auto-fluorescence as a selection 
marker, via flow-cytometry [13]. To functionally 
describe these cells, we coined the term “energetic” 
cancer stem cells (e-CSCs) [13]. Briefly, e-CSCs retain 
high expression of the senescence marker p21-WAF 
(CDKN1A), while paradoxically manifesting a hyper-
proliferative phenotype (Table 1, Right). Based on 
Ingenuity Pathway Analysis (IPA) of e-CSC proteomics 
data, other upstream regulators of cell cycle arrest and 
senescence were activated, including p53, TGFB1, and 
p38 MAPK signaling [13]. 
 
Moreover, e-CSCs show a hyper-metabolic phenotype, 
with increased mitochondrial mass, elevated oxidative 
mitochondrial metabolism, as well as enhanced glyco-
lytic function. e-CSCs mount a strong anti-oxidant 
response, characterized by increased levels of 
glutaredoxin-1 (GLRX) expression and ALDH isoform 
activity (Table 1, Right).  Interestingly, e-CSCs also 
show a number of stem-like features, including large 
cell size and anchorage-independent growth, that is 
highly sensitive to inhibitors of both mitochondrial 
OXPHOS and CDK4/6 cell cycle progression (Figure 
3). In addition, large cell size is a key feature commonly 


























Lastly, in e-CSCs, BCAS1 (Breast carcinoma-amplified 
sequence-1) protein expression was up-regulated, by 
nearly 120-fold [13].  BCAS1 over-expression [17] is 
functionally associated with “stemness” [18], a more 
aggressive cancer cell phenotype [19] and Tamoxifen-
resistance [20, 21].  MCF7-TAMR cells, which were 
chronically selected for Tamoxifen-resistance, by 
including Tamoxifen in their tissue culture media, show 
a >50-fold increase in BCAS1 protein expression, 




In summary, e-CSCs possess many of the predicted 
hallmarks that would be expected of the cancer cell of 
origin. This assertion could have broad implications for 
mechanistically understanding and more effectively 
targeting the cancer stem cell of origin, to prevent tumor 
recurrence and metastatic dissemination, throughout the 
body, to significantly improve clinical outcomes in 
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